If Remestemcel-L is given full approval (not AA) for GVHD by the FDA, then there is also the possibility of it being used 'off label' for COVID-19 ARDS while the additional trial is being conducted by Novartis ... sadly there sure seems to be a need for it in the USA regardless of the treatments available at present; daily death numbers remain stubbornly high
If Remestemcel-L is given full approval (not AA) for GVHD by the...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.040(3.60%) |
Mkt cap ! $1.227B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.13 | $1.06 | $6.561M | 6.066M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 46086 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 37234 | 9 |
View Market Depth
| Last trade - 14.26pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
-0.040 ( 1.62 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.12 | $1.06 | 1455268 | ||
| Last updated 14.48pm 31/05/2024 ? | |||||
| MSB (ASX) Chart |